UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor

The oncologist (Dayton, Ohio), 2015-06, Vol.20 (6), p.660-673

2015

Volltextzugriff (PDF)

Current Diagnosis and Management of Small-Cell Lung Cancer

Mayo Clinic proceedings, 2019-08, Vol.94 (8), p.1599-1622

2019

Volltextzugriff (PDF)

Neoadjuvant Immunotherapy for NSCLC: Current Concepts and Future Approaches

Journal of thoracic oncology, 2020-08, Vol.15 (8), p.1281-1297

2020

Volltextzugriff (PDF)

Advances in Targeting the Ras/Raf/MEK/Erk Mitogen-Activated Protein Kinase Cascade with MEK Inhibitors for Cancer Therapy

Clinical cancer research, 2008-01, Vol.14 (2), p.342-346

2008

Volltextzugriff (PDF)

Anti–PD-1 Antibody Treatment and the Development of Acute Pulmonary Tuberculosis

Journal of thoracic oncology, 2016-12, Vol.11 (12), p.2048-2050

2016

Volltextzugriff (PDF)

BRAF Alterations as Therapeutic Targets in Non–Small-Cell Lung Cancer

Journal of thoracic oncology, 2015-10, Vol.10 (10), p.1396-1403

2015

Volltextzugriff (PDF)

Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations

Journal of thoracic oncology, 2020-06, Vol.15 (6), p.914-947

2020

Volltextzugriff (PDF)

KRAS: From undruggable to a druggable Cancer Target

Cancer treatment reviews, 2020-09, Vol.89, p.102070-102070, Article 102070

2020

Volltextzugriff (PDF)

The clinical development of MEK inhibitors

Nature reviews. Clinical oncology, 2014-07, Vol.11 (7), p.385-400

2014

Volltextzugriff (PDF)

MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations

Science translational medicine, 2016-02, Vol.8 (324), p.324ra14

2016

Volltextzugriff (PDF)

Early Clinical Development of ARQ 197, a Selective, Non–ATP‐Competitive Inhibitor Targeting MET Tyrosine Kinase for the Treatment of Advanced Cancers

The oncologist (Dayton, Ohio), 2011-06, Vol.16 (6), p.788-799

2011

Volltextzugriff (PDF)

Pemetrexed (ALIMTA), A Novel Multitargeted Antineoplastic Agent

Clinical cancer research, 2004-06, Vol.10 (12), p.4276s-4280s

ADJEI, Alex A

2004

Volltextzugriff (PDF)

The Use of Radiation Therapy for the Treatment of Malignant Pleural Mesothelioma: Expert Opinion from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation

Journal of thoracic oncology, 2019-07, Vol.14 (7), p.1172-1183

2019

Volltextzugriff (PDF)

Our Work Is Done, and You Are in Good Hands

JTO clinical and research reports, 2023-01, Vol.4 (1), p.100447-100447, Article 100447

Adjei, Alex A.

2023

Volltextzugriff (PDF)

Characterization of Comorbidities Limiting the Recruitment of Patients in Early Phase Clinical Trials

The oncologist (Dayton, Ohio), 2019-01, Vol.24 (1), p.96-102

2019

Volltextzugriff (PDF)

Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial

Journal for immunotherapy of cancer, 2022-04, Vol.10 (4), p.e004424

2022

Volltextzugriff (PDF)

The Journal of Thoracic Oncology in the Next Decade

Journal of thoracic oncology, 2016-01, Vol.11 (1), p.8-8

Adjei, Alex A.

2016

Volltextzugriff (PDF)

Identification of somatic mutations in non-small cell lung carcinomas using whole-exome sequencing

Carcinogenesis (New York), 2012-07, Vol.33 (7), p.1270-1276

2012

Volltextzugriff (PDF)

Lung Cancer Worldwide

Journal of thoracic oncology, 2019-06, Vol.14 (6), p.956-956

Adjei, Alex A.

2019

Volltextzugriff (PDF)

MET: a promising anticancer therapeutic target

Nature reviews. Clinical oncology, 2012-06, Vol.9 (6), p.314-326

2012

Volltextzugriff (PDF)

The Coming of a New Age: The Journal of Thoracic Oncology Goes Electronic in 2024

Journal of thoracic oncology, 2023-10, Vol.18 (10), p.1257-1257

Adjei, Alex A.

2023

Volltextzugriff (PDF)

Effective Incorporation of Biomarkers into Phase II Trials

Clinical cancer research, 2009-03, Vol.15 (6), p.1898-1905

2009

Volltextzugriff (PDF)

Novel Designs and End Points for Phase II Clinical Trials

Clinical cancer research, 2009-03, Vol.15 (6), p.1866-1872

2009

Volltextzugriff (PDF)

Phase I Dose Escalation Study of the Anti–Insulin-Like Growth Factor-I Receptor Monoclonal Antibody CP-751,871 in Patients with Refractory Solid Tumors

Clinical cancer research, 2007-10, Vol.13 (19), p.5834-5840

2007

Volltextzugriff (PDF)

The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006

Oncogene, 2005-10, Vol.24 (46), p.6861-6869

2005

Volltextzugriff (PDF)

1 – 25 von 503

Suche als RSS-Feed

Aktive Filter

KollektionIngentaConnect Journals

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(456)
Mit Volltextzugriff
(453)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(269)
Life Sciences & Biomedicine
(266)
Humans
(240)
Oncology
(231)
Female
(97)
Male
(95)
Aged
(88)
Middle Aged
(85)
Biological And Medical Sciences
(84)
Medical Sciences
(83)
Respiratory System
(77)
Adult
(69)
Lung Neoplasms - Drug Therapy
(60)
Neoplasms - Drug Therapy
(59)
Antineoplastic Agents
(55)
Pharmacology. Drug Treatments
(54)
Tumors
(52)
Aged, 80 And Over
(50)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(50)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(49)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Journal Of Thoracic Oncology
(97)
Journal Of Clinical Oncology
(49)
Clinical Cancer Research
(37)
Cancer Research
(23)
Clinical Lung Cancer
(20)
Cancer
(17)
Investigational New Drugs
(15)
Molecular Cancer Therapeutics
(12)
Cancer Chemotherapy And Pharmacology
(8)
Lung Cancer
(8)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor

Current Diagnosis and Management of Small-Cell Lung Cancer

Neoadjuvant Immunotherapy for NSCLC: Current Concepts and Future Approaches

Advances in Targeting the Ras/Raf/MEK/Erk Mitogen-Activated Protein Kinase Cascade with MEK Inhibitors for Cancer Therapy

Anti–PD-1 Antibody Treatment and the Development of Acute Pulmonary Tuberculosis

BRAF Alterations as Therapeutic Targets in Non–Small-Cell Lung Cancer

Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations

KRAS: From undruggable to a druggable Cancer Target

The clinical development of MEK inhibitors

MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations

Early Clinical Development of ARQ 197, a Selective, Non–ATP‐Competitive Inhibitor Targeting MET Tyrosine Kinase for the Treatment of Advanced Cancers

Pemetrexed (ALIMTA), A Novel Multitargeted Antineoplastic Agent

The Use of Radiation Therapy for the Treatment of Malignant Pleural Mesothelioma: Expert Opinion from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation

Our Work Is Done, and You Are in Good Hands

Characterization of Comorbidities Limiting the Recruitment of Patients in Early Phase Clinical Trials

Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial

The Journal of Thoracic Oncology in the Next Decade

Identification of somatic mutations in non-small cell lung carcinomas using whole-exome sequencing

Lung Cancer Worldwide

MET: a promising anticancer therapeutic target

The Coming of a New Age: The Journal of Thoracic Oncology Goes Electronic in 2024

Effective Incorporation of Biomarkers into Phase II Trials

Novel Designs and End Points for Phase II Clinical Trials

Phase I Dose Escalation Study of the Anti–Insulin-Like Growth Factor-I Receptor Monoclonal Antibody CP-751,871 in Patients with Refractory Solid Tumors

The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006

Aktive Filter

Suchergebnisse filtern